Standout Papers

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer 2016 2026 2019 2022 6.9k
  1. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer (2016)
    Martin Reck, Delvys Rodríguez‐Abreu et al. New England Journal of Medicine
  2. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater (2019)
    Martin Reck, Delvys Rodríguez‐Abreu et al. Journal of Clinical Oncology
  3. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50% (2021)
    Martin Reck, Delvys Rodríguez‐Abreu et al. Journal of Clinical Oncology
  4. A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407 (2020)
    Luis Paz‐Ares, David Vicente et al. Journal of Thoracic Oncology
  5. Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study (2023)
    Silvia Novello, Dariusz M. Kowalski et al. Journal of Clinical Oncology

Immediate Impact

4 by Nobel laureates 4 from Science/Nature 73 standout
Sub-graph 1 of 20

Citing Papers

Therapy-induced senescent cancer cells contribute to cancer progression by promoting ribophorin 1-dependent PD-L1 upregulation
2025 Standout
New promises and challenges in the treatment of advanced non-small-cell lung cancer
2024 Standout
9 intermediate papers

Works of Andrew Robinson being referenced

Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study
2023 Standout
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
2021 Standout
and 3 more

Author Peers

Author Last Decade Papers Cites
Andrew Robinson 9006 6024 903 2050 131 12.8k
Donald E. White 15911 2757 1166 14850 148 26.1k
Francesco Grossi 3690 3277 446 761 318 6.7k
Yasuo Ikeda 2344 2183 2865 3031 482 19.2k
Frank Cuttitta 2847 1180 857 967 212 10.8k
Takeharu Yamanaka 4668 4381 1929 435 340 10.3k
Hitoshi Fujiwara 1364 2241 2228 563 544 9.3k
Kazuhiro Tsukada 2004 1906 2876 418 280 6.1k
Sabine Eckhardt 3780 1620 378 417 274 14.6k
Graham Packham 3061 503 332 2228 242 11.9k
Yanhua Hu 1037 982 2108 1646 187 10.4k

All Works

Loading papers...

Rankless by CCL
2026